Psoriatic Arthritis
- Coordinated therapy is directed at the skin and joints.
- Pt education, physical and occupational therapy.
- TNF modulatory agents (etanercept, infliximab, adalimumab, golimumab, certolizumab pegol) can improve joint disease and delay radiographic progression. Etanercept, infliximab, and certolizumab pegol can also be used for skin disease. Infliximab biosimilar can be used for skin and joint disease.
- Ustekinumab (anti-IL-12/23 p40 monoclonal antibody) has efficacy for both skin and joint disease.
- Apremilast (phosphodiesterase 4 inhibitor) benefit skin and joint involvement.
- Secukinumab and ixekizumab, (IL-17A antagonists), have been found to improve disease activity and can also be used for moderate to severe plaque psoriasis.
- Abatacept (CTLA4-Ig) has been used to reduce signs and symptoms of active PsA.
- Tofacitinib (Janus kinase inhibitor) used in adults with active PsA who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
- NSAIDs.
- Intraarticular steroid injections-useful in some settings. Systemic glucocorticoids should rarely be used as may induce rebound flare of skin disease upon tapering.
- Sulfasalazine 2-3 g/d has clinical efficacy but does not halt joint erosion.
- Methotrexate 15 mg/week may not be disease modifying but it may have symptom-modifying effects and can improve skin scores.
- Leflunomide may be of benefit for skin and joint disease.
|